A Phase I/II clinical trial of Carbon-ion radiotherapy for patients with immune checkpoint inhibitor resistant metastatic renal cell carcinoma

A Phase I/II clinical trial of Carbon-ion radiotherapy for patients with immune checkpoint inhibitor resistant metastatic renal cell carcinoma - CIRT for ICIs resistant metastatic RCC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1032190111

Enrollment

Registered

2019-10-07

Start date

2019-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma Metastatic renal cell carcinoma

Interventions

Carbon-ion radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Immune checkpoint inhibitor resistant metastatic renal cell carcinoma diagnosed by urologist 2) Age >20 years 3) Performance Status (ECOG), 0-2 4) Ability to understand and sign an informed consent form at each institution

Exclusion criteria

Exclusion criteria: 1) target tumors that had been treated by other radiation therapies 2) an estimated life expectancy of less than 6 months 3) the presence of active double cancers other than RCC 4) Existing untreatable infection or inflammatory disease in target volume 5) a serious medical or psychological condition precluding safe administration of treatment

Design outcomes

Primary

Measure	Time frame
Adverse event	—

Secondary

Measure	Time frame
Local control rate, local shrinkage rate, occurrence rate of Abscopal effect, progression free survival rate, overall survival rate	—

Contacts

Public ContactGoro Kasuya

QST hospital, Quantum Life and Medical Science Directorate, National Institutes for Quantum and Radiological Science and Technology

kasuya.goro@qst.go.jp+81-43-206-3306

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026